HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Best Wellness Innovation Group - Here Are the Concerns

China Resources Medical - Hard to Earn High Profits Due to Poor Business Model and Policy Risk

Micro-Tech Nanjing (688029.CH) - Potential for Reversals Despite Short-Term Pressure on Performance

Pre-IPO Gaush Meditech - The "Middlemen" Have Many Challenges

Policy Interpretation of 2022 National Medical Insurance (NRDL) Negotiation

Pre-IPO Huayiwang Technology - The Business Model Is Reasonable, but There Are Also Challenges

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Cryofocus Medtech (Shanghai) / Equity Capital Markets

<ul>
<li>The cryoablation market accounts for about 1/3 of the total tumor ablation market overseas, while this percentage is less than 1/10 in China, indicating promising growth potential in the future.</li>
<li>
<a href="https://www.smartkarma.com/entities/cryofocus-medtech-shanghai-co-ltd" target="_blank" data-smartkarma-citation="entities:35417:1" rel="noopener">Cryofocus Medtech (Shanghai) (CFM HK)</a>’s products and candidates do have technical advantages, offering more choices for patients and doctors.</li>
<li>However, the commercialization outlook remains to be seen because of the potential large price reduction after entering national medical insurance coverage and the uncertainties over acceptance by patients and doctors.</li>
</ul>


The cryoablation market accounts for about 1/3 of the total tumor ablation market overseas, while this percentage is less than 1/10 in China, indicating promising growth potential in the future.

Cryofocus Medtech (Shanghai) (CFM HK)’s products and candidates do have technical advantages, offering more choices for patients and doctors.
However, the commercialization outlook remains to be seen because of the potential large price reduction after entering national medical insurance coverage and the uncertainties over acceptance by patients and doctors.


Pre-IPO Cryofocus Medtech (Shanghai) - The Industry, the Business and the Concerns